Sponsor content
290 result(s) found, displaying 11 to 20
-
Australian public assessment report (AusPar)Pyrazinamide-AFT is indicated in adult patients of more than 12 years of age with active drug-sensitive tuberculosis caused by Mycobacterium tuberculosis. Pyrazinamide-AFT is an anti-tuberculosis agent used in combination with other anti- tuberculosis agents and is commonly used in the first 2 months of treatment.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ONDANSETRON-AFT ondansetron (as hydrochloride) 4 mg/ 5 mL oral liquid solution bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Pyrazinamide-AFT pyrazinamide 500 mg tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOXIFLOXACIN-AFT moxifloxacin (as hydrochloride) 400 mg / 250 mL intravenous infusion injection bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MAGNESIUM SULFATE-AFT magnesium sulfate heptahydrate 2.5 g/5 mL concentrated injection ampoule.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PHENYLEPHRINE-AFT phenylephrine hydrochloride 10 mg/1 mL solution for injection vial.
-
Cancellation by sponsorRequested by AFT Pharmaceuticals Pty Ltd
-
Cancellation by sponsorRequested by AFT Pharmaceuticals Pty Ltd
-
Cancellation by sponsorRequested by AFT Pharmaceuticals Pty Ltd
-
Cancellation by sponsorRequested by AFT Pharmaceuticals Pty Ltd